Japan's gasoline has hit record highs, dialysis tubing is running out, and bathtubs can't be shipped. With 95% of crude oil coming from the Middle East, pivoting to the world's largest oil producer, America, seems like a perfect Win-Win. But refinery design, tanker size, the Panama Canal bottleneck, and an ironic naphtha yield problem all stand in the way. Here's why the obvious solution isn't simple.
A JAMSTEC-University of Tsukuba team has discovered self-replicating circular RNA replicons living in 70-80°C Japanese hot springs. These newly found members of the Obelisk superfamily, a mysterious RNA entity first described by Nobel laureate Andrew Fire in 2024, expand our view of RNA-based life and may offer fresh clues to the RNA world hypothesis on the origin of life.
Tokushima University researchers led by Prof. Tomohide Saio have unveiled OptoChaperone in JACS, a biohybrid tool that uses light to reversibly switch protein droplets on and off inside living cells. A look at how this Japanese breakthrough could accelerate ALS and Alzheimer's drug discovery, and how it compares with US and European condensate startups like Dewpoint Therapeutics and Nereid.
Panasonic has partnered with Kyoto University's iPS Cell Research Foundation to begin proof-of-concept trials for fully automating iPS cell establishment at Osaka's Nakanoshima Cross. The goal: slash per-patient costs from tens of millions of yen to around 1 million yen. How does Japan's approach compare with US rival Cellino's laser-driven biomanufacturing?
Suntory Holdings is acquiring Daiichi Sankyo Healthcare, maker of Loxonin, Lulu, and Minon, for $1.55 billion. As Japan's youth abandon alcohol and the population ages rapidly, the beverage giant pivots to self-care. We analyze the deal, the booming OTC market, and what it means for global healthcare trends.
Researchers at Utsunomiya University have provided the world's first direct proof that ceramide deficiency in the skin causes atopic dermatitis. Using transgenic mice, they demonstrated the full disease cascade from barrier breakdown to allergic inflammation — opening doors for ceramide-based therapies and enzyme-targeting treatments for the 200+ million people affected worldwide.
Japan's government has approved a plan to make standard childbirth costs free by 2026. But the Japan Association of Obstetricians warns of a looming collapse in maternity care, delivery facilities have halved since 1996, and rural 'maternity deserts' are spreading. How does Japan's birth system compare to France and Sweden?
Japanese researchers cloned mice from a single donor for 20 years, producing over 1,200 animals across 58 generations. After the 27th generation, lethal mutations accumulated until all 58th-generation clones died within days of birth — the first proof that mammal cloning has a hard biological limit.
Japan's iCELL BANK launched in April 2026, offering individuals the ability to create and cryopreserve their own iPS cells for future regenerative medicine. Using ID Pharma's Sendai virus vector technology, the service marks a new phase in commercializing the Nobel Prize-winning iPS cell technology for everyday consumers.
Nobel laureate Shinya Yamanaka explained iPS Cell 2.0 on NTV's Bankisha. From next-gen stem cell tech overcoming current limitations to universal blood platelets that bypass blood-type matching, plus Japan's historic first-ever iPSC drug approvals in 2026 — a comprehensive look at where iPS cells stand 20 years after their discovery.
Fujitsu and Osaka University developed STAR Architecture ver. 3 and molecular model optimization to cut quantum computing resources to between 1/15 and 1/80 of conventional FTQC needs. Calculations for drug-critical Cytochrome P450 fall from 740,000 to 40,000 qubits and complete in 9 days. Comparison with IBM, Google, and IonQ's quantum drug discovery efforts included.
Omron announced it will sell its founding electronic components business — relays, sensors, and connectors dating back to 1933 — to U.S. private equity firm Carlyle Group at an enterprise value of ¥81 billion ($540M). A deep dive into Omron's strategic pivot to industrial automation and healthcare, and what this means for Japan's electronics industry restructuring.
Researchers at the University of Tokyo developed an AI model that integrates cine MRI imagery of uterine peristalsis with clinical data, significantly improving pregnancy prediction for patients with recurrent implantation failure. The novel approach condenses 18 seconds of uterine movement into a single image for deep learning analysis.
Not the iPS cells themselves, but the liquid they're grown in, injected into arthritic knees. A Japanese team's world-first study showed 71.4% improvement by international criteria with no serious adverse events. We look at what a seven-patient uncontrolled pilot can and cannot tell us, and where conditioned medium sits in Japan's regulations.
Japanese esports team ZETA DIVISION partners with the University of Tokyo to scientifically extend pro player careers through neuroscience research on reflexes, cognition, and motor control. Fighting game legends Momochi and Higuchi join the study.
Japanese startup Orizuru Therapeutics has begun clinical trials transplanting iPS cell-derived islet cells into diabetes patients. The first-ever transplant surgery succeeded in February 2025, with company-sponsored trials planned in Japan and the US. Over a decade after Professor Yamanaka's Nobel Prize, Japan's regenerative medicine enters the practical stage.
Shibaura Institute of Technology and AIST have measured the stable carbon isotope ratios of PFOA and PFOS, a world first for PFOS, using an Orbitrap that reads the chemical fingerprint without burning the sample. River spike tests proved it works on real environmental water, opening a path to identifying PFAS pollution sources. The bench work was a senior thesis. Japan made its 50 ng/L tap water standard legally binding in April 2026.
The Mirai Human Washing Machine, tried by 1,277 people at the 2025 Osaka Expo with 98.3% satisfaction, is now sold at Yamada Denki. The 60-million-yen ($370,000) flagship is limited to 40-50 hand-built units, alongside a 1.45-million-yen ($9,000) model aimed at care homes.
Japan's health ministry adds "Sleep Disorder" as a new medical specialty for the first time since 2008. With the shortest sleep duration among OECD nations and $100 billion in annual economic losses, Japan is officially confronting its sleep crisis.
On March 6, 2026, Japan's Health Minister formally approved ReHeart (severe heart failure) and Amshepri (Parkinson's disease), the world's first iPS cell-derived medical products. In May, Amshepri became the first iPS product covered by public insurance, priced at 55.3 million yen. Here are the conditions, the seven-year deadline, and the objections.